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ABSTRACT:
Understanding genetic aberrations in cancer leads to discovery of new targets for 
cancer therapies. The genomic landscape of hepatocellular carcinoma (HCC) has not 
been fully described. Therefore, patients with refractory advanced/metastatic HCC 
referred for experimental therapies, who had adequate tumor tissue available, had 
targeted next generation sequencing (NGS) of their tumor samples using the Illumina 
HiSeq 2000 platform (Foundation One, Foundation Medicine, MA) and their treatment 
outcomes were analyzed. In total, NGS was obtained for 14 patients (median number 
of prior therapies, 1) with advanced/metastatic HCC. Of these 14 patients, 10 (71%) 
were men, 4 (29%) women, 6 (43%) had hepatitis B or C-related HCC. NGS revealed 
at least 1 molecular abnormality in 12 patients (range 0-8, median 2). Detected 
molecular aberrations led to putative activation of the PI3K/AKT/mTOR pathway 
(n=3 [mTOR, PIK3CA, NF1]), Wnt pathway (n=6 [CTNNA1, CTNNB1]), MAPK pathway 
(n=2 [MAP2K1, NRAS]), and aberrant DNA repair mechanisms, cell cycle control and 
apoptosis (n=18 [ATM, ATR, BAP1, CCND1, CDKN2A,CDK4, FGF3, FGF4, FGF19, MCL1, 
MDM2, RB1, TP53]). Of the 3 patients with molecular aberrations putatively activating 
the PI3K/AKT/mTOR pathway, 2 received therapies including a mTOR inhibitor and all 
demonstrated therapeutic benefit ranging from a partial response to minor shrinkage 
per RECIST (-30%, -15%; respectively). In conclusion, genomic alterations are 
common in advanced HCC. Refractory patients with alterations putatively activating 
the PI3K/AKT/mTOR pathway demonstrated early signals of clinical activity when 
treated with therapies targeting mTOR.
INTRODUCTION 
The discovery of mutated “cancer genes”, 
has provided key insights into the mechanisms of 
tumorigenesis, which has been useful for developing 
targeted cancer therapies. Most recent examples include 
ALK inhibitors in non-small cell lung cancer with an ALK 
rearrangement or BRAF inhibitors in melanoma with a 
BRAF mutation.[1, 2] 
Yet, hepatocellular carcinoma (HCC) is one of the 
most common malignancies worldwide and the third 
leading cause of death after lung and gastric cancers, but 
lacks molecular targets or signatures.[3] HCC comprises 
several distinct entities defined by etiology, and often 
arises in the wake of cirrhosis and liver dysfunction. 
Most cases of HCC are associated with hepatitis B or 
hepatitis C, as well as metabolic derangements such as 
alcoholic liver disease and nonalcoholic steatohepatitis. It 
is plausible that each entity may have a different molecular 
genetic profile that determines biological behavior, 
prognosis and response to molecularly targeted therapy.
[4] Currently, complete resection or liver transplant 
Oncotarget3013www.impactjournals.com/oncotarget
are the only therapeutic approaches offering long-term 
survival. Most patients (>85%) with HCC present with 
advanced disease and about 12 months of survival on 
standard therapies.[5, 6] HCC is a highly heterogeneous 
tumor for which molecular signatures or druggable targets 
remain to be identified.  According to the COSMIC 
database, which includes data from cell lines and tumor 
samples, there have been 1,709 oncogenes with oncogenic 
mutations identified in HCC to date (accessed 2/12/2013).
[7] Mutations are primarily prevalent in TP53 (31%), 
CTNNB1 (19%), AXIN1 (16%), NFE2L2 (14%), ARID2 
(13%), and PIK3CA (7%).[7] However, systematic efforts 
to delineate the molecular profile of HCC in a large group 
of tumor samples from patients are still underway (http://
cancergenome.nih.gov/).[8] Here we report the results of 
targeted next generation sequencing (NGS) and treatment 
outcomes in a case series of 14 patients with advanced/
metastatic HCC.
RESULTS
PATIENTS
A total of 14 patients with advanced metastatic 
HCC were analyzed with NGS, of whom 10 (71%) were 
men and 4 (29%) women. Their median age at diagnosis 
was 58 years (range, 27 to 79 years) and 10 (71.5%) 
patients were White, 3 (21.5%) African American, and 1 
(7%) Asian. In addition, 3 (21.5%) patients had hepatitis 
C-related HCC, 1 (7%) hepatitis B-related HCC, 2 
(14.5%) hepatitis B and C-related HCC and 8 (57%) had 
HCC without identified predisposing factors. Patients 
received a median of 1 (range, 1-4) therapies prior to being 
referred for experimental therapies to the Clinical Center 
for Targeted Therapy (CCTT).
Molecular profiling and treatment outcomes
Patient 1, an Asian male, was diagnosed at the 
age of 56 years with hepatitis B-related HCC and was 
initially treated with a liver transplant (Table 1). At the 
time of disease recurrence, the patient received firstline 
therapy with sorafenib and progressed after 4 months. 
NGS performed on a tumor sample from the epidural 
biopsy obtained after the firstline therapy revealed an ATR 
W463* mutation and MDM2 amplification (Figure 1). 
ATR encodes the protein ataxia telangiectasia, which plays 
a key role in maintaining genomic integrity via regulation 
of DNA repair and replication (Figure 2).[9] The ATR 
W463*mutation truncates the ATR protein and is likely to 
lead to a loss of protein function. In HCC ATR mutations 
have been reported anecdotally.[7] Based on preclinical 
evidence, ATR-deficient tumors may be sensitive to PARP 
inhibitors.[9] MDM2 acts to prevent the activity of the 
tumor suppressor p53; therefore, amplification of MDM2 
may be oncogenic (Figure 2). MDM2 amplification has 
been identified according to some data in up to 44% 
of patients with HCC.[10] It is assumed that MDM2 
amplification may predict sensitivity to MDM2 inhibitors; 
however, currently available evidence is inconclusive.
[11] At the time of referral to the CCTT the patient had 
metastatic disease to lungs and bones and subsequently 
received experimental therapy with sorafenib (200 mg 
orally twice a day), temsirolimus (15 mg intravenously 
weekly), and bevacizumab (10 mg/kg intravenously every 
3 weeks), which did not match any molecular target. 
Although the patient demonstrated a 25% improvement 
per RECIST after 8 weeks of therapy, he ultimately 
progressed in his bones after 2.8 months of therapy. 
Patient 2, an African American male, was diagnosed 
at the age of 51 years with hepatitis C and cirrhosis-
related HCC (Table 1). He progressed after 1.8 months 
of firstline therapy with sorafenib. NGS performed on 
a tumor sample from the chest wall biopsy obtained 
at the time of diagnosis revealed PIK3CA mutation 
H1047R, CTNNB1 mutation S37C, and protein tyrosine 
phosphatase delta (PTPRD) mutation S1845fs*2 
(Figure 1). PIK3CA encodes the active subunit of 
phosphatidylinositol 3-kinase (PI3K), which regulates 
cell growth, proliferation, differentiation, motility and 
survival (Figure 2).[12] Mutations in PIK3CA have been 
reported in 7% of liver cancer cases.[7] Preclinical and 
early clinical data suggest that activating mutations in 
PIK3CA may predict sensitivity to inhibitors of the PI3K/
AKT/mTOR pathway.[12-14] CTNNB1 encodes beta-
catenin, a key component of the Wnt signaling pathway 
(Figure 2). CTNNB1 exon 3 mutations, such as S37C, are 
considered to be activating and lead to activation of the 
Wnt pathway.[15] CTNNB1 mutations have been reported 
in 19% of HCC.[7] PTPRD, a tumor suppressor, plays an 
essential role in dephosphorylating STAT3 (Figure 2).[16] 
Mutations in PTPRD occur only sporadically in HCC 
(1%).[7]  S1845fs*2 is a frameshift mutation that truncates 
the PTPRD protein within the second tyrosine phosphatase 
domain (amino acids 1644-1903) only 1 amino acid 
from the phosphatase active site, possibly resulting in an 
inactive protein. At the time of referral to the CCTT the 
patient had metastatic disease to the mediastinum, bones, 
and liver and subsequently received experimental therapy 
with a mTOR inhibitor sirolimus (4 mg orally daily) in 
combination with a histone deacetylase inhibitor (HDAC) 
vorinostat (300 mg orally daily), which was matching a 
molecular abnormality in the PI3K/AKT/mTOR pathway 
(PIK3CA H1047R mutation) and attained 15% shrinkage 
per RECIST. He progressed after 3.8 months.[17] Then 
he received a mTOR inhibitor everolimus (10 mg orally 
every other day) and multikinase inhibitor pazopanib 
(600 mg orally every other day), which again targeted the 
PI3K/AKT/mTOR pathway and induced 11% shrinkage 
per RECIST after 2 months, but he progressed after a 
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Figure 1: Overview of mutations in 14 patients with hepatocellular carcinoma. The heatmap shows gain of function mutations 
(green), loss of function mutations (red), mutations with unknown effects (yellow), copy number variations (blue), and rearrangements 
(purple). 
Figure 2: Major pathways altered by somatic mutations, copy number variations or rearrangements in 14 patients 
with hepatocellular carcinoma
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total of 2.9 months. The patient then received the EGFR 
inhibitor erlotinib (100 mg orally daily) and antimetabolite 
praletrexate (15 mg/m2 intravenously weekly for 3 weeks 
followed by a week off), which did not match any of the 
detected abnormalities and progressed after 2.1 months 
with no initial response.
Patient 3, a White male, was diagnosed at the age 
of 59 years with hepatitis C-related HCC and history of 
hepatitis B. He was initially treated with a liver transplant. 
At the time of the second disease recurrence he progressed 
on firstline therapy with sorafenib after 5.9 months. 
NGS of a tumor sample obtained from a lung resection 
performed at the time of the first recurrence after the initial 
liver transplantation revealed RB1 loss (Figure 1). RB1 
encodes the retinoblastoma protein, a tumor suppressor 
and negative regulator of the cell cycle (Figure 2).[18] 
The loss of RB1 protein expression has been linked to 
poor survival and may prognosticate a decreased response 
to kinase inhibitors.[18] RB1 mutations have been 
reported sporadically in HCC.[7] At the time of referral 
to the CCTT the patient had metastatic disease to the 
right pterygoid fossa and liver and his clinical condition 
precluded experimental therapy.
Patient 4, a White male, was diagnosed at the age of 
57 years with hepatitis C, hepatitis B, and alcohol-related 
HCC. He was initially treated with liver transplantation 
and at the time of disease recurrence he received firstline 
therapy with sorafenib and progressed after 7 months. 
NGS performed on the tumor sample from the liver 
transplant after diagnosis revealed CTNNB1 mutation 
Table 1: Characteristics of patients with molecular aberrations who received experimental therapies
Patient 
number Sex Ethnicity
Age at 
diagnosis 
(years)
Subtype
Number of 
prior systemic 
therapies
Metastatic 
spread
Mutations 
(expected 
consequence)
Copy 
number 
variations
Rearrangements Experimental therapy (target)
Therapy 
matching 
target
RECIST 
(%)
Time to 
progression 
(months)
1 Male Asian 56 HCC, hepatitis B 1 Lungs, bones
ATR (impaired 
DNA repair 
and cell cycle 
control)
MDM2 
(reduced 
apoptosis)
None
Sorafenib, 
temsirolimus, 
bevacizumab
No -25 2.8
2 Male African-American 51
HCC, hepatitis 
C, cirrhosis 1
Mediastinum, 
bones, liver
PIK3CA 
(PI3K/mTOR 
activation), 
CTNNB1 (Wnt 
activation), 
PTPRD (STAT3 
activation)
None None
Sirolimus 
(mTOR), 
vorinostat 
(HDAC)
Yes -15 3.8
Everolimus 
(mTOR), 
pazopanib 
(multikinase)
Yes -11 2.9
Erlotinib 
(EGFR), 
praletrexate 
(antifolate 
analog)
No
+11 (PD 
in non-
target 
lesions)
2.1
6 Male White 61 HCC, hepatitis C, cirrhosis 1
Liver, adrenal 
glands, bones
CTNNA1 (Wnt 
activation), 
CTNNB1 (Wnt 
activation)
None None
Oxaliplatin 
(DNA damage), 
bevacizumab 
(VEGF), 
capecitabine 
(antimetabolite)
No +13 3.2
7 Female African-American 46 HCC 4
Lungs, 
mediastinum, 
liver, 
peritoneum
NF1 (PI3K/
mTOR and 
MAPK 
activation), 
CTNNB1 (Wnt 
activation)
None
BAP1 (loss of 
interaction with 
BRCA1)
Everolimus 
(mTOR), 
pazopanib 
(multikinase)
Yes -30 8.3
8 Female African-American 56
HCC with 
cholangio-
carcinoma
3
Lungs, 
mediastinum, 
liver, 
peritoneum, 
porta hepatis
BAP1 (loss of 
interaction with 
BRCA1)
None None
Sirolimus
(mTOR)
No +130 1.4
Nab-paclitaxel 
(mitotic 
inhibitor), 
bevacizumab 
(VEGF), 
gemcitabine 
(antimetabolite) 
No
+15 
(clinical 
PD)
1.6
12 Male White 66 HCC 2 Liver
CDKN2A 
(loss of p16 
function), 
ARID1A (SWI/
SNF chromatin 
remodeling 
complex)
CCND1 
(impaired 
cell cycle 
control), 
FGF3,4,19 
(impaired 
cell cycle 
control)
None MET kinase inhibitor No +14 4
14 Female White 53 HCC 2
Lungs, 
mediastinum, 
liver
Rb1 loss (loss 
of cell cycle 
control)
None None
Oxaliplatin 
(DNA damage), 
bevacizumab 
(VEGF), 
capecitabine 
(antimetabolite)
No -18 2.9
Abbreviations: mTOR, mammalian target of rapamycin; HDAC, histone deacetylase; PI3K, phosphoinositide 3-kinase; EGFR, epidermal growth factor receptor 
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I35S, and TP53 V143M mutation (Figure 1). The CTNNB1 
gene plays a role in the Wnt signaling pathway and is 
characterized in detail above and the I35S mutation is 
considered to be activating (Figure 2).[15] Functional loss 
of tumor suppressor p53, which is encoded by the TP53 
gene, is common in advanced cancers (Figure 2).[19] 
TP53 V143M mutation is located within the DNA-binding 
domain of the p53 protein, which is thought to result in loss 
of function.[20] Mutations of TP53 have been reported in 
31% of cases of HCC.[7] A recent meta-analysis reported 
that HCC patients with TP53 alterations experienced 
significantly shorter recurrence-free survival and overall 
survival.[19] There are no approved therapies to address 
TP53 mutations; however, tumors with TP53 mutations 
may be sensitive to Wee1 inhibitors, which are in clinical 
trials. At the time of referral to the CCTT the patient had 
metastatic disease to the lungs, liver, retroperitoneum, and 
bones. He did not receive experimental therapy because of 
insurance denial.
Patient 5, a White male, was diagnosed at the age 
of 66 years with hepatitis C-related HCC. He was initially 
treated with sorafenib and progressed after 15.5 months; 
however, during that period of time he also underwent 
transarterial chemoembolization of the liver. NGS of a 
tumor sample obtained from a liver biopsy performed at 
the time of diagnosis revealed CDKN2A mutation H83Y 
and CTNNB1 mutation T41A (Figure 1). The CDKN2A 
gene encodes the tumor suppressor p16(Ink4a), which 
plays a vital role in cell cycle G1 checkpoint regulation 
and its deletion contributes to inactivation of the p16-
CDK4/Cyclin/Rb pathway and loss of cell cycle control 
(Figure 2).[21] The CDKN2A H83Y mutation leads to a 
reduced ability to induce cell cycle arrest. CTNNB1, a key 
component of the Wnt signaling pathway, is characterized 
above (Figure 2).[15] CTNNB1 exon 3 mutations, such as 
T41A, are considered to be activating the Wnt pathway.
[22] At the time of referral to the CCTT the patient had 
metastatic disease to the liver and decided to pursue 
therapeutic options outside of MD Anderson.
Patient 6, a White male, was diagnosed at the age 
of 61 years with hepatitis C-related HCC (Table 1). He 
was initially treated with sorafenib and progressed after 
4.5 months. NGS of a tumor sample obtained from a 
bone biopsy performed at the time of diagnosis revealed 
CTNNA1 mutation K889* and CTNNB1 mutation 
T41A (Figure 1). The CTNNA1 gene plays a role in cell 
adhesion downstream in the Wnt signaling pathway 
(Figure 2).[15] The CTNNA1 K889* mutation is expected 
to be inactivating; however, its functional consequencies 
are not fully understood. CTNNB1, a key component 
of the Wnt signaling pathway, is characterized above 
(Figure 2).[15] CTNNB1 exon 3 mutations, such as 
T41A, are considered to be activating the Wnt pathway.
[22] At the time of referral to the CCTT the patient had 
metastatic disease to his liver, adrenal glands and bones 
and subsequently received experimental therapy with 
hepatic arterial infusion oxaliplatin (140 mg/m2 every 
3 weeks), intravenous bevacizumab (10 mg/kg every 
3 weeks) and oral; capecitabine (1500 mg/m2 on days 
1-4 every 3 weeks) and progressed after 2.2 months. 
The experimental therapies did not match any detected 
molecular abnormality.
Patient 7, an African American female, was 
diagnosed at the age of 46 years with HCC (Table 
1). She progressed on firstline therapy with sorafenib 
after 2.1 months. Then she progressed after 1.3 months 
of experimental therapy with an oncolytic virus and 
ultimately responded very well to a combination 
of bevacizumab and erlotinib, which she received 
twice with a PFS of 16.8 months and 10.1 months, 
respectively. NGS performed on a tumor sample from a 
liver biopsy obtained at the time of diagnosis revealed 
NF1 mutation R1241*,  BAP1 truncation (exon 12), 
and CTNNB1 mutation N387K (Figure 1). NF1 encodes 
neurofibromin 1, a GTPase-activating protein (GAP) that 
is a key negative regulator of the RAS and PI3K signaling 
pathway (Figure 2).[23] The NF1 R1241* mutation leads 
to a nonsense codon, resulting in truncation of the NF1 
protein within the GAP-related domain, which is likely 
to negate tumor suppressing activity. NF1 mutations 
have been reported in 10% of HCC samples and such 
tumors may thus be sensitive to PI3K/AKT/mTOR and 
MAPK inhibitors.[7, 24] BAP1 rearrangement results in 
a truncation of the BAP1 protein (Figure 2). The resulting 
truncated protein product is believed to be nonfunctional.
[25] BAP1 rearrangements have not been previously 
reported in HCC.[7] While there are no therapies that 
directly target BAP1 loss, HDAC inhibitors are being 
explored based on the results of a preclinical study.[26] 
CTNNB1, a key component of the Wnt signaling pathway, 
is characterized above (Figure 2).[15] N387K is a rare 
mutation, located in the region responsible for binding to 
APC.[27] N387K has not been characterized, but other 
mutations in this region were shown to abrogate APC 
binding, although beta catenin was still degraded in the 
presence of these mutations.[27] The functional effect of 
N387K is unknown. At the time of referral to the CCTT the 
patient had metastatic disease to her lungs, mediastinum, 
peritoneum and liver and subsequently received the 
experimental therapy with mTOR inhibitor everolimus 
(7.5 mg orally every other day) and multikinase inhibitor 
pazopanib (600 mg orally every other day), which was 
matched to a molecular abnormality activating the PI3K/
AKT/mTOR pathway (NF1 R1241*mutation). Restaging 
CT scans revealed a PR (-30% per RECIST), which was 
maintained for the total of 8.3 months. Then the patient 
received the mTOR inhibitor sirolimus (5 mg orally daily) 
and HDAC inhibitor vorinostat (300 mg orally daily), 
which again targeted the PI3K/AKT/mTOR pathway and 
was due to have her first reassessment after 2 months at 
the time of analysis.
Patient 8, an African American female, was 
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diagnosed at the age of 56 years years with HCC with 
islands of cholangiocarcinoma (Table 1). She underwent 
a left hepatectomy and at the time of disease recurrence 
was treated with firstline therapy sorafenib and progressed 
after 10.7 months. Then she received a combination 
of oxaliplatin and gemcitabine and progressed after 
6.6 months, followed by treatment with 5-fluorouracil, 
leucovorin, irinotecan, and bevacizumab, but progressed 
after 1.6 months. NGS performed on a tumor sample 
from the liver resection obtained at the time of diagnosis 
revealed BAP1 mutation L65* (Figure 1). A BAP1 L65* 
mutation in this tumor results in a truncation of the BAP1 
protein near the amino terminus. Details about BAP1 are 
outlined above (Figure 2) [25]. At the time of referral to 
the CCTT the patient had metastatic disease to her lungs, 
mediastinal and hilar nodes, porta hepatis, peritoneum, 
and liver and subsequently received experimental therapy 
with mTOR inhibitor sirolimus (4 mg orally daily). She 
progressed after 1.4 months and then received hepatic 
arterial infusion nab-paclitaxel (180 mg/m2 every 3 
weeks) and intravenous bevacizumab (10 mg/kg every 
3 weeks) and gemcitabine (800 mg/m2 on days 1 and 8 
every 3 weeks) and progressed after 1.6 months. None of 
the experimental therapies was matched to any detected 
molecular abnormalities.
Patient 9, a White male, was diagnosed at the age of 
65 years with HCC, which was initially treated with a right 
hepatectomy and radiofrequency ablation. At the time of 
disease recurrence he was treated on firstline therapy with 
cisplatin, interferon, adriamycin, and 5-fluorouracil and 
remained progression-free for 23.7 months. He was next 
treated with capecitabine and progressed after 1.8 months, 
then treated on a clinical trial with regorafenib for 49.3 
months and then with sorafenib, but progressed after 1.7 
months. NGS performed on a tumor sample from the 
liver resection obtained at the time of diagnosis revealed 
mTOR mutation S2215Y and FLT3 mutation splice 
site 1418+2A>G (Figure 1). mTOR acts downstream 
of multiple pathways, including the PI3K/AKT/mTOR 
pathway (Figure 2). This mTOR S2215Y mutation is 
located in the kinase domain.[28] The S2215Y mutation 
has been reported to result in constitutive activation of 
mTOR complex 1 (mTORC1) but not mTORC2 and to 
retain sensitivity to sirolimus.[29] Mutations in mTOR 
have not yet been reported in HCC.[7] FLT3 encodes a 
receptor tyrosine kinase. Signaling through the FLT3 
pathway leads to phosphorylation of SHC1 and AKT1 
and activation of mTOR, as well as RAS activation and 
phosphorylation of ERK1 and 2 (Figure 2).[30] The 
1418+2A>G splice site mutation seen in this tumor 
disrupts the canonical GT splice-donor site of the 5’ end 
of the intron separating exon 11 and exon 12; however, 
the resulting GC dinucleotide sequence has been reported 
as a non-canonical splice site in the human genome.[31] 
Mutation of the conserved 5’ GT splice site often results 
in exclusion of the neighboring exon, but may also result 
in truncation of the encoded protein.[32] This alteration 
has not been previously reported and its consequences 
are difficult to predict. Among FDA approved therapies 
sorafenib is known to be a FLT3 inhibitor and regorafenib 
also has weak anti-FLT3 activity.[33] At the time of 
referral to the CCTT the patient had metastatic disease 
to the liver and spleen. The patient did not receive 
experimental therapy due to his worsening performance 
status.
Patient 10 (White female diagnosed with HCC at the 
age of 67 years) had no molecular abnormality revealed 
through NGS.
Patient 11, a White male, was diagnosed at the age 
of 70 years with HCC, which was initially treated with a 
right partial hepatectomy. At the time of disease recurrence 
he was treated on firstline therapy with sorafenib and was 
taken off therapy after 4.6 months because of squamous 
cell carcinomas related to sorafenib therapy. NGS 
performed on a tumor sample from the liver resection 
performed at the time of disease recurrence revealed 
ATM mutation K53fs*3 and a TP53 A161S and M160I 
mutations. In addition, MET, CDK4, MAP2K1, MCL1, 
MDM2, NRAS amplifications were found (Figure 1). ATM 
encodes the protein ataxia telangiectasia mutated, which 
plays a key role in sensing double-strand DNA breaks 
and activating cellular checkpoint pathways, arresting the 
cell cycle when DNA damage is present (Figure 2).[34] 
ATM K53fs*3 mutation is predicted to be inactivating 
due to loss of most of the ATM protein, including the 
kinase domain. According to the COSMIC database ATM 
mutations were found in all 4 tested HCC samples.[7] 
Preclinical evidence suggested that ATM deficient tumors 
may be sensitive to PARP inhibitors.[35] Functional loss 
of TP53 is common in aggressive advanced cancers and 
is described in detail above (Figure 2).[19] Both A161 
and M160 are located within the DNA-binding domain of 
TP5. While the A161S mutation is predicted to be severe, 
the M160I mutation is predicted to be non-severe.[36] 
DNA-binding domain mutations are thought to result in 
loss of function.[20] MET encodes a receptor tyrosine 
kinase that is activated by the ligand HGF, and MET 
activation promotes angiogenesis, resistance to apoptosis, 
proliferation, and invasion of cancer cells (Figure 2).[37] 
MET amplification has been reported in 2% of HCC.
[38] MET amplification may predict sensitivity to MET 
inhibitors, some of which are FDA approved (crizotinib, 
cabozantinib).[39] CDK4 encodes cyclin-dependent 
kinase 4, which, along with functional homolog CDK6 
and family member CDK2, regulates cell cycle G1 phase 
progression and the G1/S transition (Figure 2).[40] CDK4 
amplification has been reported in 2% of HCC samples.
[38] There are currently no approved therapies that 
directly target CDK4; however a number of drugs are 
under investigation in clinical trials. MAP2K1 (also known 
as MEK1) encodes the signaling protein mitogen-activated 
protein kinase kinase 1. MEK1 phosphorylates the ERK1/2 
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proteins in the RAS/RAF/MEK pathway (Figure 2).[41] 
MAP2K1 amplification has been reported in 2% of HCC 
samples.[38] The relationship between MEK amplification 
and sensitivity to MEK inhibitors is unknown. MCL1 
encodes the protein MCL1, which is a member of the 
BCL2 family and can result in antiapoptotic activity 
(Figure 2).[42] MCL1 amplification has been reported in 
12% of HCC.[38] There are no FDA approved therapies 
to address MCL1 copy number amplification at this time, 
but investigations focused on small molecule inhibitors of 
MCL1 are underway. In addition, the multikinase inhibitor 
sorafenib has been shown to down-regulate MCL1 and 
thereby induce apoptosis in preclinical studies.[43] Also, 
preclinical studies of patient-derived tumor cells suggest 
that increased MCL1 levels may confer resistance to 
antitubulin therapies such as paclitaxel.[44] MDM2 acts 
to prevent the activity of the tumor suppressor p53 and its 
function is described in detail above.[10] NRAS encodes a 
member of the RAS family of small GTPases that mediate 
transduction of growth signals (Figure 2).[41] Activation 
of RAS signaling causes cell growth, differentiation, and 
survival by activating the RAF/MAPK/ERK, PI3K, and 
other pathways. NRAS amplification has not been reported 
in HCC.[38] There are no approved therapies to address 
cancers associated with NRAS amplification or activating 
mutations. NRAS putatively leads to activation of the 
RAF/MEK/ERK pathway. Therefore, NRAS activation 
might theoretically predict sensitivity to MEK inhibitors. 
At the time of referral to the CCTT the patient had 
metastatic disease to the liver, but decided not to receive 
experimental therapy.
Patient 12, a White male, was diagnosed at the 
age of 79 years with idiopathic cirrhosis-related HCC 
(Table 1). He progressed after 2.7 months of firstline 
therapy with sorafenib. Then he received experimental 
therapy with bevacizumab and erlotinib and progressed 
after 3.8 months. NGS performed on a tumor sample 
from the liver biopsy obtained at the time of diagnosis 
revealed CDKN2A mutation A102P, ARID1A mutation 
I1485fs*5, CCND1 amplification, FGF19 amplification, 
FGF3 amplification and FGF4 amplification (Figure 1). 
CDKN2A regulates the p16-CDK4/Cyclin/Rb pathway 
and is characterized above (Figure 2).[21] The CDKN2A 
A102P mutation has not been characterized, but it is 
likely to be inactivating.[45] Overall, CDKN2A mutations 
has been reported in 8% of HCC.[7] ARID1A encodes 
the AT-rich interactive domain-containing protein 1A, a 
member of the SWI/SNF chromatin remodeling complex. 
ARID1A is believed to function as a tumor suppressor 
and deletion of ARID1A can lead to tumor formation.
[46] The I1485fs*5 mutation results in truncation of the 
protein and similar truncations have been predicted to be 
inactivating.[46] ARID1A mutations have been reported 
in HCC in the COSMIC database.[7] CCND1 encodes 
Cyclin D1, which interacts with the cyclin-dependent 
kinases CDK4 and Cdk6, resulting in inactivation of 
RB1 and progression of the cell cycle. Amplification of 
CCND1 may therefore lead to increased proliferation. 
CCND1 amplification has been reported in 4% of HCC.
[47] FGF3 encodes fibroblast growth factors 19, an 
FGFR4 ligand involved in regulation of hepatic protein 
and glycogen metabolism.[48] FGF3  plays a central 
role in development of the inner ear and FGF3 germline 
mutations give rise to an autosomal recessive syndrome 
characterized by microdontia, deafness and complete 
lack of inner ear structures.[49] FGF4 plays a central role 
in tooth development.[50] At the time of referral to the 
CCTT the patient had metastatic disease to the liver and 
subsequently received experimental therapy with oral an 
daily dose of an experimental MET kinase inhibitor, which 
did not match any detected molecular abnormality. He had 
stable disease (+14% per RECIST) and progressed after 
4.0 months. 
Patient 13 (White male diagnosed with HCC at the 
age of 27 years) had no molecular abnormality revealed 
through NGS.
Patient 14, a White female, was diagnosed at the 
age of 53 years with HCC (Table 1). She progressed 
after 6 months of firstline therapy with sorafenib. Then 
she received experimental therapy with bevacizumab and 
erlotinib and progressed after 1.8 months. NGS performed 
on a tumor sample from the liver biopsy obtained at the 
time of diagnosis revealed RB1 loss (Figure 1). RB1 
encoding the Rb protein is characterized above (Figure 
2).[18] At the time of referral to the CCTT the patient had 
metastatic disease to her lungs, mediastinum and liver and 
subsequently received experimental therapy with hepatic 
arterial infusion oxaliplatin (140 mg/m2 every 3 weeks), 
intravenous bevacizumab (10 mg/kg every 3 weeks) and 
oral capecitabine (1500 mg/m2 on days 1-4 every 3 weeks) 
and was taken off therapy after 2.9 months because of 
poor tolerance. The experimental therapies did not match 
any detected molecular abnormality.
DISCUSSION
Targeted NGS analysis of tumor samples from 14 
consecutive patients with advanced HCC refractory to 
standard therapies referred to the CCTT for experimental 
therapies with targeted agents revealed that 12 (86%) 
patients had at least one somatic molecular aberration 
(median, 2; range, 0-8) in their tumor samples (activating 
mutations, n=6; loss of function mutations, n=10; 
mutations with unknown effects, n=6; copy number 
variations, n=11; rearrangements, n=1) and 9 (64%) had 
more than one molecular aberration. Of interest, molecular 
aberrations were found in the PI3K/AKT/mTOR pathway 
(mTOR, n=1; PIK3CA, n=1; NF1, n=1), Wnt pathway 
(CTNNA1, n=1, CTNNB1, n=5), the MAPK pathway 
(MAP2K1, n=1; NRAS, n=1), DNA repair mechanisms, 
cell cycle control and apoptosis (ATM, n=1, ATR, n=1; 
BAP1, n=2, CCND1, n=1; CDKN2A, n=2; CDK4, n=1; 
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FGF3, n=1; FGF4, n=1, FGF19, n=1; MCL1, n=1; 
MDM2, n=2; RB1, n=2; TP53, n=2). Six (43%) patients 
with HCC in the context of hepatitis B (n=1), hepatitis C 
(n=3) or both (n=2) had molecular abnormalities related 
to the PI3K/AKT/mTOR pathway (PIK3CA, n=1), Wnt 
pathway (CTNNA1, n=1; CTNNB1, n=4), STAT3 signaling 
(PTPRD, n=1), DNA repair mechanisms, cell cycle control 
and apoptosis (ATR, n=1; CDKN2A, n=1; RB1, n=1; 
MDM2, n=1; TP53, n=1). Despite the fact that several 
patients had aberrations in some genes such as CTTNB1 
and CDKN2A,  the specific combination of aberrations 
and their subtypes were unique to each individual patient, 
important distinctions for selecting personalized cancer 
therapies.
Patients with hepatitis B or C-related HCC had a 
median of 2 aberrations (range, 1-3), which was similar 
to a median of 1.5 aberration in patients without hepatitis 
(range, 0-8; p = 0.74).  To date, the molecular landscape 
of HCC has not been clearly defined and major initiatives 
such as The Cancer Genome Atlas are in progress. Only 
limited data on copy number variations are available, 
demonstrating that MCL1, and BAP1 are the most frequent 
copy number abnormalities (12%, 4%, respectively).
[38] According to the COSMIC database, the genes 
most frequently mutated include TP53 (31%), CTNNB1 
(19%), AXIN1 (16%), NFE2L2 (14%), ARID2 (13%), 
and PIK3CA (7%).[7] An integrated analysis of somatic 
mutations and focal copy number variations with whole 
exome sequencing of 24 HCC cases revealed recurrent 
mutations in CTNBB1 (46%), AXIN1 (21%), TP53 (13%), 
CDKN2A (8%), and ARID2 (8%).[51] CTTNB1 was also 
the most frequently mutated gene in our study (5/14, 
36%). Of interest mTOR mutation S2215Y has never been 
reported before in HCC. 
Of the 14 patients in our study, 3 (21%) had 
genomic alterations putatively activating the PI3K/AKT/
mTOR pathway and 2 such patients received therapies 
that included an mTOR inhibitor. Both patients had some 
therapeutic benefit ranging from a PR to minor shrinkage 
per RECIST (-30%, -15%; respectively), which was 
maintained for 3.8 months and 8.3 months. According to 
the COSMIC database, with the exception of PIK3CA, 
none of the mutations putatively leading to PI3K/AKT/
mTOR activation are commonly found in HCC; however, 
preclinical models and early clinical data generally 
suggest that targeting the PI3K/AKT/mTOR pathway can 
be an effective strategy in subsets of patients with HCC.
[52, 53] However, none of the studies investigated these 
therapies in HCC with PI3K/AKT/mTOR activation.[54, 
55] Revisiting such studies with gating of HCC patient for 
alterations in the PI3K/AKT/mTOR pathway may yield 
better evidence of the efficacy of inhibitors of the PI3K/
mTOR pathway in this difficult to treat disease.[56-58]  
In conclusion, we have identified multiple molecular 
abnormalities in a small data set of patients with advanced 
HCC. Interestingly, a proportion of our patients had 
molecular aberrations putatively associated with PI3K/
AKT/mTOR pathway activation and these patients 
attained some benefit (although not always durable) 
from targeting the PI3K/AKT/mTOR pathway. Despite 
several limitations such as small patient numbers, absence 
of randomization and control groups, our data suggest 
that comprehensive molecular profiling can increase our 
knowledge of HCC biology to an unprecedented level, 
which can be translated to patient care.
PATIENTS AND METHODS
Patients
We reviewed the electronic medical records of 
consecutive patients with advanced/metastatic HCC 
(excluding fibrolamellar type given its distinct entity and 
natural history) referred to the CCTT at MD Anderson 
Cancer Center. Data were collected from transcribed notes 
and radiology reports in the electronic medical record and 
other source documentation. Registering patients in the 
database, clinical, pathologic, laboratory and pathology 
assessment were performed at MD Anderson. The study 
and all treatments were conducted in accordance with 
the guidelines of the MD Anderson Institutional Review 
Board. 
Molecular analysis
Archival tumor samples obtained from standard 
diagnostic or therapeutic procedures were tested with 
Clinical Laboratory Improvement Amendment-certified 
targeted NGS (Foundation One, Foundation Medicine, 
MA) using the Illumina HiSeq 2000 platform. Genomic 
libraries were captured for 3,230 exons representing the 
complete coding sequence of 182 cancer-related genes 
plus 37 introns from 14 genes often rearranged in cancer 
and sequenced to an average median depth of 734X with 
99% of bases covered >100X. On January 1, 2013, the 
platform was upgraded to cover 3,769 exons of 236 
cancer-related genes and 47 introns from 19 genes to an 
average depth of 1000X. 
Treatment
Patients were enrolled in clinical trials according 
to the discretion of treating physicians and availability 
of clinical trials at the time of enrollment. Treatment 
continued until disease progression or unacceptable 
toxicity. Treatment was carried out according to the 
specific requisites in the treatment protocols selected.  
Assessments, including history, physical 
examination, and laboratory evaluations, were performed 
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as specified in each protocol, typically before the initiation 
of therapy, weekly during the first cycle, and then, at a 
minimum, at the beginning of each new treatment cycle. 
Response was assessed from computed tomography 
(CT) scans and/or magnetic resonance imaging (MRI) 
at baseline before treatment initiation and then every 
2 cycles (6-8 weeks). All radiographs were read in the 
Department of Radiology at MD Anderson and reviewed 
in the Department of Investigational Cancer Therapeutics 
tumor measurement clinic. Responses were categorized 
per RECIST criteria and categorized as complete response 
(CR); partial response (PR), stable disease (SD) or 
progressive disease (PD).[17] 
Statistical analysis
Mann-Whitney test was used to assess the 
association between continuous variables. All tests were 
two-sided, and P values less than 0.05 were considered 
statistically significant. All statistical analyses were carried 
out using SPSS 19 computer software (SPSS Chicago, IL).
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